Q1 2019 Biogaia AB Earnings Call Transcript
Ladies and gentlemen. Welcome to the BioGaia Q1 report 2019. Today, I'm pleased to present Isabelle Ducellier, CEO; and Margareta Hagman, CFO. (Operator Instructions) Speakers, please begin.
()-
Yes, good morning and thank you. Isabelle here. Welcome to my second telephone conference, but this time regarding the quarter 1 2019.
I would like to underline 4 dimensions regarding this quarter. Next slide, please. The first one is that we have actually strong sales growth of our products in both Pediatrics and Adult segment. And especially in Adult segment, we have an increase by 54%.
Secondly, I would like as well to emphasize strong sales growth for BioGaia Protectis drops; BioGaia Protectis tablets, which is quite unusual, so it's worth mentioning it; and BioGaia Prodentis lozenges mainly driven by Japan.
Thirdly, I think it is very worth noticing that we have extremely strong growth in the Asia Pacific region, with Quarter 1 at plus 80%. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |